Skip to content
Home/Companies/Pharma/Curapath
Curapath

Curapath

Pharma·Spain·Exited 2021·Held 4yr
Entry
2017
Hold
4yr
Exit
2021

Who owns Curapath?

Curapath was owned by Columbus Venture Partners through Columbus Innvierte Life Science Fund I (2016 vintage) from 2017 to 2021, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-08-09

Columbus Venture Partners
Investor
Columbus Venture Partners
Columbus Innvierte Life Science Fund I · 2016 · Life Sciences VC

Key facts

HQSpain
SectorPharma
StatusAcquired
Websitecurapath.com
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2021

More from Columbus Innvierte Life Science Fund I

Other portfolio companies in the same fund.

Artax Biopharma
Artax Biopharma
Active
BiotechUnited States· 2020
Aura Biosciences
Exited 2021
BiotechUnited States· 2018
TAAV
Exited 2020
BiotechSpain· 2018
to
Viralgen
Exited 2020
BiotechSpain· 2018
to
Algenex
Exited 2022
BiotechSpain· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFrance· 2017

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Laboratoires Delbert
Active
SocadifFrance
AMW
AMW
Active
SHS Gesellschaft für BeteiligungsmanagementGermany· 2026
Basic Pharma
Active
SHS Gesellschaft für BeteiligungsmanagementNetherlands· 2026
Cinclus Pharma
Cinclus Pharma
Active
Claret Capital PartnersSweden· 2026
InfoRLife
Active
BC PartnersSwitzerland· 2026
IRAB
IRAB
Active
ARCHIMEDSpain· 2026
Track Curapath

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Curapath.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue